Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab versus tacrolimus for primary membranous nephropathy in adults with type 2 diabetes mellitus
ChiCTR2000032523Phase 4Not yet recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of rituximab and tacrolimus in idiopathic membranous glomerulonephritis (IMG) (2 arms), sponsored by Xinqiao Hospital. Primary endpoints: Complete remission, Partial remission and 1 more. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
rituximabtacrolimus
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on ChiCTR2000032523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032523.